Despite therapeutic drug monitoring and pharmacogenetic-guided dose selection are recommended for pediatric patients, safety of voriconazole is mostly monitored by clinical assessment. Having comprehensive knowledge of safety profile and distinguishing incidental events from the reactions that are truly related to voriconazole use are crucial for safer and uninterrupted treatment.
Objectives
This study aimed to address adverse reactions during the first month of voriconazole use by systematically evaluating retrospective records of all adverse events. Patients/Methods: It is a single-center, retrospective analysis of patients who received voriconazole from 1 September 2010 to 1 September 2020. Severity of abnormal findings in medical records were systematically graded. Causality between voriconazole and the events was evaluated by Liverpool Causality Assessment Tool (LCAT), Naranjo Algorithm and World Health Organization Causality Assessment System. The events with possible or probable causal relation to voriconazole are classified as adverse reaction.
Results
Records of 45 patients included in the study. The overall frequency of adverse reactions was 51.1%. Hepatobiliary laboratory adverse reactions identified in 48.9% of the patients and led to treatment discontinuation in 20.0%. Amylase and lipase elevation (2.2%), ventricular extra systoles (2.2%), hallucination and nightmares (2.2%) were other adverse reactions.
Conclusions
Hepatobiliary abnormalities were the most common adverse reactions and the most common cause of treatment discontinuation. For safer treatment in critically ill patients, the dose should be personalized. To clearly identify the accurate frequency and the causality of all adverse reactions, prospective studies with much larger sample size are needed.
PanaZDRoilidesEWarrisA, et al.Epidemiology of invasive fungal disease in children. J Pediatric Infect Dis Soc2017; 6: S3–S11.
2.
UllmannAJAguadoJMArikan-AkdagliS, et al.Diagnosis and management of aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect2018; 24: e1–e38.
3.
WarrisALehrnbecherTRoilidesE, et al.ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children. Clin Microbiol Infect2019; 25: 1096–1113.
4.
PattersonTFThompsonGRDenningDW, et al.Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis2016; 63: e1–e60.
5.
GrollAHCastagnolaECesaroS, et al.Fourth European conference on infections in leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol2014; 15: e327–e340.
MoriyamaBObengAOBarbarinoJ, et al.Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy. Clin Pharmacol Ther2017; 102: 45–51.
8.
LamoureuxFDuflotTWoillardJ-BB, et al.Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections. Int J Antimicrob Agents2016; 47: 124–131.
9.
TrubianoJACroweAWorthLJ, et al.Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort. J Antimicrob Chemother2015; 70: 1161–1165.
JinHWangTFalcioneBA, et al.Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis. J Antimicrob Chemother2016; 71: 1772–1785.
GallagherRMKirkhamJJMasonJR, et al.Development and inter-rater reliability of the liverpool adverse drug reaction causality assessment tool. PLoS ONE2011; 6: e28096.
14.
NaranjoCABustoUSellersEM, et al.A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981; 30: 239–245.
ZoniosDYamazakiHMurayamaN, et al.Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype. J Infect Dis2014; 209: 1941–1948.
17.
Solís-MuñozPLópezJCBernalW, et al.Voriconazole hepatotoxicity in severe liver dysfunction. J Infect2013; 66: 80–86.
18.
MichaelCBierbachUFrenzelK, et al.Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients. Antimicrob Agents Chemother2010; 54: 3225–3232.
19.
LevinMDden HollanderJGvan der HoltB, et al.Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. J Antimicrob Chemother2007; 60: 1104–1107.
20.
BoastACurtisNCranswickN, et al.Voriconazole dosing and therapeutic drug monitoring in children: experience from a paediatric tertiary care centre. J Antimicrob Chemother2016; 71: 2031–2036.
21.
PieperSKolveHMeineT, et al.Safety and outcome of treatment with voriconazole in a large cohort of immunocompromised children and adolescents. GMS Infect Dis 2015; 3: Doc01.
22.
DenningDWRibaudPMilpiedN, et al.Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis2002; 34: 563–571.
23.
Den HollanderJGVan ArkelCRijndersBJ, et al.Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections. J Antimicrob Chemother2006; 57: 1248–1250.
24.
LuongM-LHosseini-MoghaddamSMSingerLG, et al.Risk factors for voriconazole hepatotoxicity at 12 weeks in lung transplant recipients. Am J Transplant2012; 12: 1929–1935.
25.
AmiguesICohenNChungD, et al.Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant2010; 16: 46–52.
26.
MitsaniDNguyenMHShieldsRK, et al.Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother2012; 56: 2371–2377.
27.
PhilipASivaprakasamPSagarTG, et al.Voriconazole-induced pancreatitis in a patient of acute myeloid leukemia and invasive aspergillosis. J Pediatr Hematol Oncol2012; 34: 406.
28.
DoltonMJRayJEChenSC-A, et al.Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother2012; 56: 4793–4799.
29.
EidenCPeyrièreHCociglioM, et al.Adverse effects of voriconazole: analysis of the French pharmacovigilance database. Ann Pharmacother2007; 41: 755–763.
30.
ZoniosDIGea-BanaclocheJChildsR, et al. Hallucinations during voriconazole therapy. Clin Infect Dis; 47. Epub ahead of print 1 July 2008. DOI: 10.1086/588844.
WalshTJKarlssonMODriscollT, et al.Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother2004; 48: 2166–2172.
33.
PhilipsJAMartyFMStoneRM, et al.Torsades de pointes associated with voriconazole use. Transpl Infect Dis2007; 9: 33–36.
34.
AyparEKendirliTTutarE, et al.Voriconazole-induced QT interval prolongation and torsades de pointes. Pediatr Int2011; 53: 761–763.
35.
BrownJDLimLLKoningS. Voriconazole associated torsades de pointes in two adult patients with haematological malignancies. Med Mycol Case Rep2014; 4: 23–25.
36.
GuetaILoebsteinRMarkovitsN, et al.Voriconazole-induced QT prolongation among hemato-oncologic patients: clinical characteristics and risk factors. Eur J Clin Pharmacol2017; 73: 1181–1185.
37.
AlkanYHaefeliWEBurhenneJ, et al.Voriconazole-induced QT interval prolongation and ventricular tachycardia: a non-concentration-dependent adverse effect. Clin Infect Dis2004; 39: e49–e52.
38.
XingYChenLFengY, et al.Meta-analysis of the safety of voriconazole in definitive, empirical, and prophylactic therapies for invasive fungal infections. BMC Infect Dis2017; 17: 798.
39.
ChuHYJainRXieH, et al.Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events. BMC Infect Dis2013; 13: 105.
40.
WalshTJPappasPWinstonDJ, et al.Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med2002; 346: 225–234.
41.
TanKBrayshawNTomaszewskiK, et al.Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol2006; 46: 235–243.
42.
SheuJHawrylukEBGuoD, et al.Voriconazole phototoxicity in children: a retrospective review. J Am Acad Dermatol2015; 72: 314–320.
43.
DenningDWGriffithsCEM. Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin Exp Dermatol2001; 26: 648–653.
44.
BernhardSKernland LangKAmmannRA, et al.Voriconazole-induced phototoxicity in children. Pediatr Infect Dis J2012; 31: 769–771.
45.
Van HasseltJGCVan EijkelenburgNKAHuitemaADR, et al.Severe skin toxicity in pediatric oncology patients treated with voriconazole and concomitant methotrexate. Antimicrob Agents Chemother2013; 57: 2878–2881.
46.
GoyalRK. Voriconazole-associated phototoxic dermatoses and skin cancer. Expert Rev Anti Infect Ther2015; 13: 1537–1546.
SharpMTHornTD. Pseudoporphyria induced by voriconazole. J Am Acad Dermatol2005; 53: 341–345.
49.
DolanCKHallMABlazesDL, et al.Pseudoporphyria as a result of voriconazole use: a case report. Int J Dermatol2004; 43: 768–771.
50.
PatelARTurnerMLBairdK, et al.Voriconazole-induced phototoxicity masquerading as chronic graft-versus-host disease of the skin in allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant2009; 15: 370–376.
51.
LevineMTChandrasekarPH. Adverse effects of voriconazole: over a decade of use. Clin Transplant2016; 30: 1377–1386.
52.
WilliamsKManshMChin-HongP, et al.Voriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients. Clin Infect Dis2014; 58: 997–1002.
53.
FeistALeeROsborneS, et al.Increased incidence of cutaneous squamous cell carcinoma in lung transplant recipients taking long-term voriconazole. J Hear Lung Transplant2012; 31: 1177–1181.
54.
EpaulardOVillierCRavaudP, et al.A multistep voriconazole-related phototoxic pathway may lead to skin carcinoma: results from a French nationwide study. Clin Infect Dis2013; 57: e182–e188.
55.
ZwaldFOSprattMLemosBD, et al.Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation. Dermatologic Surg2012; 38: 1369–1374.
56.
EpaulardOSaint-RaymondCVillierC, et al.Multiple aggressive squamous cell carcinomas associated with prolonged voriconazole therapy in four immunocompromised patients. Clin Microbiol Infect2010; 16: 1362–1364.
57.
VadnerkarANguyenMHMitsaniD, et al.Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients. J Hear Lung Transplant2010; 29: 1240–1244.
58.
SingerJPBokerAMetchnikoffC, et al.High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients. J Hear Lung Transplant2012; 31: 694–699.
59.
CowenEWNguyenJCMillerDD, et al.Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol2010; 62: 31–37.
60.
MillerDDCowenEWNguyenJC, et al. Melanoma associated with long-term voriconazole therapy. Arch Dermatol2010; 146: 300–304.
